October 22, 2018
Interim results 2018 and perspective on activity. Read the Press Release
Interim results 2018 and perspective on activity. Read the Press Release
Biophytis obtains a €10 million loan with Kreos Capital. Read the Press Release
Biophytis Provides Enrollment Update in Its Phase 2b SARA-OBS and SARA-INT Studies of Sarconeos in Sarcopenia. Read the Press Release
BIOPHYTIS to Present at the H.C. Wainwright 20th Annual Global Investment Conference. Read the Press Release
Biophytis appoints a new Chief Medical Officer based in the USA. Read the Press Release
Results of the Extraordinary General Meeting held on June 4, 2018. Passing of all the resolutions. Read the Press Release
Biophytis receives favourable opinion from EMA for the Orphan Drug designation of Sarconeos in Duchenne Muscular Dystrophy (DMD). Read the Press Release
Inclusion of the first patient in Phase 2b Study in Sarcopenia. Read the Press Release
Results of the 2018 Annual Meeting of Shareholders. Read the Press Release